CSPC Pharmaceutical (HKG:1093) said positive topline results from the phase III equivalence clinical trial of the Secukinumab Injection have been obtained, a Thursday Hong Kong bourse filing said.
The study showed the drug has a favorable safety profile.
The product has been developed by unit CSPC Megalith Biopharmaceutical for the treatment of moderate to severe plaque psoriasis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments